Overview
Description
Alzinova AB is a biotechnology company specializing in the research and development of therapies for Alzheimer's disease. The primary focus of Alzinova is to develop safe and effective treatments aimed at addressing the underlying causes of this neurodegenerative disorder. A notable feature of the company's product pipeline is its proprietary AβCC peptide technology, which is designed to selectively target toxic amyloid-beta oligomers, a known contributor to Alzheimer's pathology. This targeted approach aims to reduce the cognitive decline associated with the disease by mitigating the harmful effects of these oligomers on brain cells. Alzinova AB operates in the highly specialized biopharmaceutical sector, where advancements in medical science hold the promise of transforming patient outcomes. By concentrating on a disease that affects millions worldwide, the company occupies a critical role in the ongoing quest to combat Alzheimer's, fostering hope for innovative solutions in disease management. Headquartered in Sweden, Alzinova collaborates with research institutions and clinical partners, leveraging their scientific expertise to advance its therapeutic candidates through various stages of clinical development.
About
CEO
Dr. Carol Routledge
Employees
5
Address
GoCo House
Entreprenörsstråket 10
Mölndal, 431 53
Entreprenörsstråket 10
Mölndal, 431 53
Phone
46 7 08 46 79 75
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Sweden
MIC code
XSTO